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Oral doses of either iopronic acid (4.5 g Oravue, Squibb) or iopanoic acid (3 gTelepaque, Winthrop) were
given to 98 patients requiring cholecystography. Radiographs were taken 13 to 16 hours after treatment
showed good to excellent gallbladder opacification in 44 percent of patients after the first dose of iopronic
acid and in an additional 29 percent after a second dose. Similar opacification occurred in 42 percent of
patients after the first dose of iopanoic acid and in 34 percent after a second dose. Drug-related abnormalities
in blood and urine tests occurred about equally in both groups and one patient in each group exhibited a
clinically adverse reaction (diarrhea). Thus, the performance (radiographic efficacy and drug safety) of the
new contrast agent, iopronic acid, was similar to a widely used drug, iopanoic acid.
An important problem associated with the use of iopanoic acid for oral cholecys-
tography is the frequent failure to produce diagnostically suitable gallbladder
opacification with the initial dose[1]. Thisfailure necessitates repeating the examina-
tion to avoid false-positive diagnoses since many of these patients subsequently are
shown not to have cholecystopathology or hepatic disorders [2]. lopanoic acid also
suffers from the disadvantage of producing an appreciable incidence of side-effects
such as diarrhea, nausea, and transitory impairment of hepatic and renal function
[3-8]. Although manipulation of diet [4,8] and drug regimen [9,10] can increase the
incidence of adequate opacification, developing a new drugthat produces fewer side-
effects and more consistent gallbladder opacification would be a major improvement
in oral cholecystography.
In the early seventies, Bracco Chemical Industries of Milan, Italy, synthesized and
tested a new compound, iopronic acid (3-acetylamino-2,4,6-triiodophenoxy-ethoxy-
methyl butanoic acid), which showed promise as an agent for oral cholecystography
[11]. lopronic acid was similar to other oral cholecystographic agents in being a
triiodinated derivative of benzene but was different in the composition of the
alkanoic side-chain, the moiety responsible for the molecule's lipophilic and hydro-
philic properties. lopronic acid was found to be superior to iopanoic acid not only in
terms of intestinal absorption and biliary excretion but also in having a higher oral
and intravenous LD 50 [11,12]. These early animal studies also showed that iopronic
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All rights of reproduction in any form reserved.acid gave better gallbladder opacification than iopanoic acid [11]. Furthermore,
toxicity to kidneys, liver, and cardiovascular system was found to be lower for
iopronic acid than for iopanoic acid in studies on rats, dogs, and rabbits [13,14].
Although not yet approved for clinical use in the United States, iopronic acid
(Bilimiro, Bracco) was tested in Italy on over 1,100 patients with suspected liver,
gallbladder, and intestinal disorders [14]. Oral doses of 3 to 9 g iopronic acid were
reported to produce satisfactory gallbladder opacification in about 90 percent of
these patients. Adverse side-effects to this drug occurred in less than 5 percent and
these included transitory nausea, vomiting, and diarrhea.
Limited clinical trials have been conducted at several U.S. institutions but very
little information has yet been published. What is available indicates that a single
dose of 4.5 g iopronic acid (Oravue, Squibb) is effective in producing satisfactory.
opacification in normal subjects [15]. In another study, the same dosage of Oravue
yielded good or excellent opacification in 88 percent of 180 patients; two patients
experienced clinically adverse reactions that were limited to erythema and pruritic
rash [16]. Side-effects from iopronic acid treatment were observed as abnormalities
of laboratory test results, and these indicated transitory impairment of hepato-biliary
or renal function in 38 of 90 patients (42 percent).
In order to examine further the usefulness of iopronic acid for oral cholecystogra-
phy, we compared the efficacy and safety of iopronic acid to iopanoic acid in a
double-blind study on patients requiring cholecystography.
SUBJECTS AND METHODS
Patients requiring oral cholecystography, usually because of suspected cholecys-
topathy, non-specific abdominal pain, or as part of a general radiological examina-
tion, were randomly assigned to receive either iopronic acid or iopanoic acid. The
iopronic acid group consisted of 17 men and 31 women averaging 49 years of age
(range, 17 to 84) and weighing 63.9 kg (range, 47.7 to 117). The iopanoic acid group
consisted of 17 men and 33 women averaging 47.9 years of age (range, 19 to 75) and
weighing 62.7 kg (range, 46.4 to 91.8 kg). None of these patients had received
cholecystographic agents within one week of the start of the study, nor had any
received intravenous pyelographic or angiographic contrast agents within 48 hours.
Excluded from the study were pregnant women and patients with severe gastrointes-
tinal disorders, ischemic heart disease, hyperthyroidism, homozygous sickle cell
disease, phenochromocytoma, multiple myeloma, or moribund patients.
Shortly after consuming a fat-free evening meal, the patients received, by blind
assignment, an oral dose of either 4.5 g iopronic acid (nine 500 mg capsules Oravue,
Squibb) or 3 g iopanoic acid (six 500 mg tablets Telepaque, Winthrop). The amount
of iodine in each dose was 2.55 g for iopronic acid and 2 g for iopanoic acid. After
taking the drug, patients were permitted to ingest only water until the radiological
examination was completed. Posterior-anterior films were made before drug admin-
istration and again 13, 14, 15, and 16 hours later. The radiographs were evaluated by
a radiologist, other than the principal investigator, without knowing the patient's
identity, the drug used, or the sequence offilms. These films were rated on a scale of0
to 3, based on the degree of opacification ofthe gallbladder and on the suitability for
diagnosis: 0-no opacification; 1-fair opacification but not adequate for diagnosis;
2-good opacification and adequate for diagnosis; 3-excellent opacification and
optimal for diagnosis. Patients whose films were scored 0 or 1 were given a second
dose of the same drug 24 hours after the first dose and another series of radiographs
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was made 13, 14, 15, and 16 hours after the second dose. These patients followed the
same regimen used with the first dose.
Samples ofblood and urine were collected from each patient before drugtreatment
and again 16 to 64 hours later, and in some cases, seven days later. Urine samples
were examined for protein and glucose, red and white blood cells, microscopic casts
and crystals; and the pH and specific gravity were measured. Blood samples were
used for standard hemograms and for determining serum uric acid, BUN, serum
transferases (SGOT and SGPT), alkaline phosphatase, lactate dehydrogenase
(LDH), total bilirubin, hepatitis B antigen, cholesterol, calcium, phosphorus, serum
protein, albumin, glucose, creatinine, and creatinine clearance. Additionally, each
patient was given a physical examination before drug administration and 16 hours
afterwards; vital signs were monitored before and 0.5, 1, and 16 hours after the initial
dose of contrast agent. On 48 patients, a physical examination was also performed at
64 hours. Thirteen patients received electrocardiographic examinations before and at
least one time after drug treatment; all these studies were found to be normal before
and after drug treatment.
Analysis of pretreatment tests indicated that renal function was normal in 93
percent of patients in the iopronic acid group and in 88 percent of the iopanoic acid
group. On the basis of abnormally high BUN (24 mg/ 100 ml or more) and serum
creatinine levels (1.6 mg/ 100 ml or more) renal function was moderately to severely
impaired in 6 percent of patients in the iopronic acid group and in 8 percent of the
iopanoic acid group. Pretreatment concentrations of serum bilirubin (normal range
.1-1.3 mg/ 100 ml) were less than 1 mg/ 100 ml in 85 percent of the iopronic acid
group and 88 percent of the iopanoic acid group. In 13 percent of both groups,
bilirubin levels were 1 to 2 mg/ 100 ml. Of the remaining two patients, both in the
iopronic acid group, one had a bilirubin level of 2.1 to 3.0 mg/ 100 ml, and the other
was not determined.
RESULTS
Maximum gallbladder opacification yielding good or excellent visualization ofthe
gallbladder was achieved in 21 patients (44 percent) after the first dose of iopronic
acid and in 14 patients (29 percent) after a second dose. In 32 of these 35 patients,
maximum opacification was first observed 13 hours after either the first or second
dose. Of the 35 patients whose gallbladders were sufficiently opacified for diagnostic
purposes, 26 were diagnosed as being normal, 8 had cholelithiasis, and I had
adenomyomatosis. The radiographs of the remaining 13 patients were scored 0 or 1;
and of these, four showed maximum opacity (rated 1) after the first dose while seven
failed to show any opacification (rated 0 after both doses). These 13 patients with
inadequate opacification did not seem to have any symptoms in common that could
account for the failure of the drug to opacify the gallbladder, although before drug
treatment, two of these patients had slightly elevated serum bilirubin levels (1-2
mg/ 100 ml) and one had levels between 2.1 and 3 mg/ 100 ml.
With iopanoic acid, maximum opacification producing good or excellent visualiza-
tion of the gallbladder was achieved in 21 patients(42 percent) with thefirst dose and
in 17(34 percent) after a second dose. In a manner similarto iopronic acid, maximum
opacification was first seen with iopanoic acid 13 hours after either the first or second
dose in 35 ofthese 38 patients. Ofthe 38 patients who achieved diagnostically suitable
opacification, 28 had normal cholecystograms, and nine had cholelithiasis. The
remaining 12 patients (24 percent) had films rated 0 or 1; of these, only two showed
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maximum gallbladder opacification with the first dose, and six failed to show any
detectable opacification. As with the iopronic acid group, these patients did not
appear to have any clinical symptoms or characteristics in common that could
account for the failure of iopanoic acid to opacify the gallbladder, although two
patients had slightly elevated bilirubin levels (1-2 mg/ 100 ml) prior to drug
administration. Although good to excellent opacification was achieved in a slightly
higher percentage ofpatients given iopanoic acid (76 percent) than was observed with
iopronic acid (73 percent) (refer to Table 1), this difference was not statistically
significant by chi-square test (p > .05).
Clinically adverse reactions occurred in one patient in each drug group. In one
case, a moderately severe diarrhea occurred three hours after the first dose of
iopanoic acid and lasted for 48 hours; and in the second case, mild diarrhea lasted for
about seven hours after taking iopronic acid.
In each group there were a number of drug-related changes in blood and urine
chemistry that suggested transitory impairment ofhepato-biliary or renal function or
both. Of the 22 patients in the iopronic acid group that showed abnormalities oftest
results, 11 exhibited changes of hepato-biliary function parameters. In these patients
at least one of the following parameters was elevated beyond the normal laboratory
range 16 hours after drug treatment: LDH, SGOT, or serum bilirubin. As indicated
by elevated serum urinary nitrogen, urinary protein, serum creatinine, or creatinine
clearance, five patients given iopronic acid had impaired renal function. Also, two
patients given iopronic acid had changes in function parameters that indicated
impairment of both hepato-biliary and renal function.
Of the 50 patients given iopanoic acid, 21 had abnormal laboratory test results. In
six patients, the changes suggested impairment of hepato-biliary function; and in
seven others renal function parameters were abnormal. Two of these 20 patients
appeared to have impairment of both renal and hepato-biliary function.
Abnormalities of blood cell counts occurred in six patients given iopronic acid and
in five patients given iopanoic acid. The most frequent changes were increases in
neutrophils and decreases in lymphocytes after iopronic acid, and an increase in
eosinophils with iopanoic acid.
DISCUSSION
Our study of 98 patients, who were representative ofpatients usually requiring oral
cholecystography, indicated that there was little difference between iopronic acid and
iopanoic acid in terms of both radiographic efficacy and drug safety. In fact, these
two drugs appeared to be essentially equal in terms of degree and rapidity of
TABLE I
The Degree of Gallbladder Opacification Achieved in Patients Receiving Either lopronic Acid or Iopanoic Acid
Degree of lopronic lopanoic
Gallbladder Acid, Acid,
Opacification No. of patients No. of patients
Good to
Excellent
(rated 2 or 3) 35 (72.9%) 38 (76.0%)
Fair (rated 1) 7 (14.61%) 6 (12.0%)
None (rated 0) 6 (12.5%) 6 (12.0%)
TOTAL 48 50
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gallbladder opacification, quality ofradiographic image for visualizing cholelithiasis,
and in the incidence of drug-associated laboratory test abnormalities and adverse
reactions. Our clinical results are similar to those reported by Pizzolato and
colleagues [16]. They found that iopronic and iopanoic acids given to patients
requiring oral cholecystography resulted in diagnostically suitable gallbladder opaci-
fication in about 88 percent of the patients, and associated with both drugs was a
similar frequency of adverse reactions and abnormalities in laboratory test results.
The conclusions regarding the similarities in diagnostic efficacy of the two drugs
must be tempered with the realization that pathological correlation data are not
available for non-opacification findings with iopronic acid. Data for iopanoic acid,
on the other hand, suggest that examinations with this drug are highly accurate in
predicting the presence of gallbladder pathology. Mujahed and colleagues retrospec-
tively studied 5,000 cases involving oral cholecystography with iopanoic acid [17]. All
152 patients having surgery after exhibiting two non-opacification studies and not
showing any evidence of extrinsic causes for non-opacification were found to have
cholecystopathology. Similar types of data are needed for iopronic acid before a
comprehensive judgment can be made about its diagnostic efficacy.
The finding that iopronic acid is neither better nor worse than iopanoic acid for
opacifying the gallbladder is somewhat surprising since early laboratory tests
suggested iopronic acid was a superior drug in terms of intestinal absorption, biliary
excretion, and gallbladder opacification [1 1]. lopronic acid is highly soluble in water,
2. 1 g/ 100 ml at 370 C, pH 6.5 [18], and this property should enhance its absorption.
On the other hand, the low water solubility ofiopanoic acid is an important deterrent
to intestinal absorption and contributes to the frequent failure of first dose opacifica-
tion [19,20]. Estimates suggest that from 20 to 53 percent of patients with apparently
normal liver, biliary, and gallbladder function do not develop diagnostically ade-
quate gallbladder opacification with the initial dose ofiopanoic acid [8,10]. However,
our observations suggest that the higher water solubility of iopronic acid was not
sufficient to alter the final outcome of the test as the degree of gallbladder
opacification was about the same for the two drugs. This suggests that the failure of
the two drugs to produce opacification in patients with normal hepato-biliary
function is either not significantly limited by the water solubility of the drug or that
the potential increase in efficacy of iopronic acid from its higher water solubility is
counter-balanced by other factors different from those influencing the efficacy of
iopanoic acid. Although our data are not sufficient to provide additional insight into
why these two different drugs seem to behave similarly under clinical conditions, it is
possible that the higher aqueous solubility of iopronic acid merely favors a more
rapid uptake of the drug from the small bowel. This could then result in an earlier
opacification. Such a difference, however, would only be apparent on radiographs
taken at times earlier than those used in the present study. Furthermore, administer-
ing iopanoic acid with a fat-free meal may have reduced its radiographic efficacy.
Stanley and coworkers [4] found that a higher percentage of patients achieved
satisfactory gallbladder opacification when iopanoic acid was given with a fatty meal
than when given with a fat-free meal (70 percent vs. 47 percent).
Finally, it is possible that significant improvements in oral cholecystography may
not be forthcoming from new molecular designs; what is now availabl-e may be nearly
chemically and pharmacologically optimal. Rather, additional improvement in
radiographic efficacy may have to depend upon better methods for administration.
Different regimens of drug administration have been tested, and some have been
found to enhance the effectiveness of the contrast agent to yield diagnostically
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suitable gallbladder opacification. Divided drug doses [9,10] and timing of adminis-
tration with respect to fatty and non-fatty meals[4,8] have led to some improvements
in the past. Of the many factors influencing drug efficacy, bile salts and alkalinity in
the intestinal tract significantly enhance uptake ofiopanoic acid [17,18]. It is possible
that additional studies on the factors influencing intestinal uptake, blood transport,
and metabolism of contrast agents may further illuminate these processes and
provide the basis for additional improvements in drug efficacy.
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